Cell Therapy: Forge Biologics Labcorps collobration aims to accelerate gene therapy


Forge Biologics and Labcorp have entered into a collaboration to accelerate gene therapy development and commercialization. Forge Biologics is a gene therapy-focused contract development and manufacturing organization, while Labcorp is a leading global life sciences company that provides diagnostic and drug development services.

The collaboration aims to leverage Forge Biologics' expertise in adeno-associated virus (AAV) gene therapy development and Labcorp's capabilities in clinical trial management, biomarker analysis, and diagnostic testing to accelerate the development of gene therapies. As part of the collaboration, Labcorp will provide clinical trial testing and biomarker analysis services, while Forge Biologics will provide AAV gene therapy development and manufacturing services.

The collaboration will initially focus on advancing Forge Biologics' gene therapy pipeline, including its lead product candidate, FBX-101, for the treatment of Krabbe disease. The companies plan to expand the collaboration to include other gene therapy programs in the future.

Overall, this collaboration has the potential to accelerate the development and commercialization of gene therapies, which could have a significant impact on the treatment of genetic diseases.

Comments

Popular posts from this blog

What precisely is Computational Biomedicine?

On this World Multiple Sclerosis Day, keep an eye out for indicators of weariness, weakness, and muscle spasms

What are the top three regenerative medicine grants?